Tag: epilepsy drugs market forecast

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Epilepsy Drugs Market?

In recent times, there has been a significant increase in the size of the epilepsy drugs market. It is anticipated that this market will expand from $10.34 billion in 2024 to $11.13 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. This growth over the historic period can be linked to the creation of improved antiepileptic drugs, advancements in diagnostic methods, a more in-depth comprehension of the neurological foundations of epilepsy, an upsurge in demand for epilepsy therapies, and the green light for new medications from regulatory bodies.

In the coming years, the epilepsy drugs market is projected to experience robust growth, rising to “$14.71 billion by 2029,” indicating a compound annual growth rate (CAGR) of 7.2%. This anticipated growth over the forecast period can be traced back to factors such as the expansion of personalized medicine, the emergence of new drug delivery methods, the rise of digital health solutions, significant R&D investments, and the incorporation of AI and ML. Key trends foreseen during the forecast period include a shift towards combination therapies, an increase in telemedicine’s prominence, a focus on drug-resistant epilepsy, an amalgamation of genetic testing, and the use of wearable technology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Epilepsy Drugs Market?

The increasing incidence of people diagnosed with epilepsy is anticipated to boost the epilepsy drug market’s expansion. Epilepsy is a neurological condition marked by recurring seizures of variable severity and significant impact on daily life routines. It is often found in elderly individuals, and those who have survived traumatic brain injuries (TBIs), strokes, brain tumors, and other neurological disorders are more susceptible to epilepsy. The drugs designed to treat epilepsy primarily function to stabilize the brain’s electrical activity, hence reducing the chances and severity of seizures, and consequently helping manage and regulate epilepsy. For instance, the World Health Organization, a US-based international agency, reported in February 2024 that about 5 million people globally receive an epilepsy diagnosis each year. The incidence is approximately 49 cases per 100,000 people in high-income countries every year, while the number can skyrocket to 139 cases per 100,000 in low to middle-income countries. Consequently, the upswing in people diagnosed with epilepsy fuels the epilepsy drug market’s growth.

Which Sub-Segments Are Driving Growth Within The Epilepsy Drugs Market?

The epilepsy drugs market covered in this report is segmented –

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures

2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics

3) By Route Of Administration: Oral, Intravenous, Intra-Muscular

4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies

Subsegments:

1) By Focal Seizures: Simple Focal Seizures, Complex Focal Seizures

2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal), Absence Seizures (Petit Mal), Myoclonic Seizures, Tonic Seizures, Atonic Seizures

3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES), Functional Seizures

What Future-Focused Trends Are Anticipated In The Epilepsy Drugs Market?

Leading enterprises within the epilepsy drug market are prioritizing the creation of innovative treatments in an effort to enhance seizure control and subsequent patient quality of life. These innovative treatments could encompass new drug formulas, cutting-edge neurostimulation techniques, precision medicine based on the individual’s needs, gene therapies, and new technologies like closed-loop systems for the detection and intervention of seizures. As an example, Akumentis Healthcare, a pharmaceutical firm based in India, released Clasepi, a prescribed cannabidiol (CBD) drug specifically concocted to treat seizures related to Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients who are a year old and upwards, in January 2024. Given its approval by the Drug Controller General of India (DCGI), it has shown to be effective in reducing seizures, especially in instances where traditional anti-seizure medicines have failed.

Who Are The Dominant Players In The Epilepsy Drugs Market Today?

Major companies operating in the epilepsy drugs market are Pfizer Inc., SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc., Bausch Health Companies Inc., UCB S.A, Sun Pharmaceutical Industries Ltd., Eisai Co Ltd., Sumitomo Pharma Co Ltd., Jazz Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd., Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc., Upsher-Smith, Zogenix, Neurelis Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

How Do Regional Dynamics Influence The Epilepsy Drugs Market Performance?

North America was the largest region in the epilepsy drugs market in 2024. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15564&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Remicade Biosimilar Sector?

In recent times, the epilepsy drugs market has experienced robust growth. The market size is anticipated to increase from $10.34 billion in 2024 to $11.13 billion in 2025, clocking a compound annual growth rate (CAGR) of 7.7%. This considerable growth in the past period is credited to the evolution of antiepileptic drugs, progresses in diagnostic methods, enhanced knowledge of the neurological foundation of epilepsy, rising demand for epilepsy therapy, and the green light given by regulatory bodies for the introduction of new drugs.

Expectations are high for robust expansion in the epilepsy drugs market over the coming years, with projections reaching “$14.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. Factors fuelling this growth in the predicted period include the rise of personalized medicine, the adoption of groundbreaking drug delivery techniques, the advent of digital health solutions, the surge in R&D funding, and the union of AI and ML. Key trends for this forecast period encompass the move towards combination therapies, the emergence of telemedicine, a focus on drug-resistant epilepsy, the incorporation of genetic testing, and the use of wearable devices.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp

What Forces Are Driving The Growth Of The Remicade Biosimilar Market?

The remicade biosimilar market is anticipated to expand due to an increase in the prevalence of autoimmune diseases. These conditions involve the immune system erroneously damaging the body’s tissues and organs. As an effective treatment option, remicade biosimilars are used to manage the symptoms and lower the inflammation that comes with these diseases. For example, according to Public Health Scotland’s data in July 2023, in 2022, the number of newly diagnosed multiple sclerosis (MS) patients rose to 87.2%, an increase from 85.7% in 2020, with 491 new cases documented, adding up to a total of 6,359. Therefore, the escalating prevalence of autoimmune diseases is proving to be a significant growth driver for the remicade biosimilar market.

The epilepsy drugs market covered in this report is segmented –

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures

2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics

3) By Route Of Administration: Oral, Intravenous, Intra-Muscular

4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies

Subsegments:

1) By Focal Seizures: Simple Focal Seizures, Complex Focal Seizures

2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal), Absence Seizures (Petit Mal), Myoclonic Seizures, Tonic Seizures, Atonic Seizures

3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES), Functional Seizures

What Are The Leading Trends And Opportunities In The Remicade Biosimilar Sector?

Key companies in the epilepsy drug market are concentrating their efforts on the creation of breakthrough therapies to enhance seizure management and better the lives of patients. These innovative solutions for epilepsy might include new drug compositions, sophisticated neurostimulation methods, individualized precision medicine solutions, gene treatments, and rising technologies like closed-loop systems for identification and intervention of seizures. For example, Akumentis Healthcare, a pharmaceutical company based in India, introduced Clasepi in January 2024, a prescribed cannabidiol (CBD) medicine specifically made to manage seizures in patients suffering from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome or Tuberous Sclerosis Complex (TSC) aged one year and up. It has received approval from the Drug Controller General of India (DCGI) and has proven to be successful in lowering seizures, particularly in situations where traditional anti-seizure drugs have failed.

Which Companies Currently Dominate The Competitive Landscape In The Remicade Biosimilar Industry?

Major companies operating in the epilepsy drugs market are Pfizer Inc., SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc., Bausch Health Companies Inc., UCB S.A, Sun Pharmaceutical Industries Ltd., Eisai Co Ltd., Sumitomo Pharma Co Ltd., Jazz Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd., Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc., Upsher-Smith, Zogenix, Neurelis Inc

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Which Geographic Regions Are Driving Demand In The Remicade Biosimilar Market?

North America was the largest region in the epilepsy drugs market in 2024. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15564&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Epilepsy Drugs Market Expected to Grow Between 2025 And 2029?#_x000D_

There has been a robust expansion in the market size of epilepsy drugs in the recent past. The market, which was worth $10.34 billion in 2024, is anticipated to rise to $11.13 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the historic period include the invention of novel antiepileptic drugs, progress in diagnosis methods, an amplified comprehension of the neurological foundations of epilepsy, a heightened demand for treatment of epilepsy, and the sanction of new medications by regulatory bodies._x000D_

_x000D_

The market size for epilepsy drugs is projected to experience considerable growth in the upcoming years, expanding to $14.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. This growth during the predicted period is influenced by aspects such as the spread of personalized medicine, the introduction of innovative drug delivery techniques, the rise of digital health solutions, heightened investment in research and development, and the incorporation of artificial intelligence and machine learning. Significant trends anticipated during this projection period encompass the shift towards combination therapies, the emergence of telemedicine, focus on drug-resistant epilepsy, integration of genetic testing, and the adoption of wearable devices._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Epilepsy Drugs Industry?#_x000D_

The increase in individuals diagnosed with epilepsy is anticipated to fuel the growth of the epilepsy drug market. Epilepsy is a neurological condition characterized by repeated seizures which can range in severity and disrupt daily activities. This disorder is more common among the elderly and individuals who have survived traumatic brain injuries, strokes, brain tumors, and other neurological disorders, as they are at a higher risk of developing epilepsy. Epilepsy medications function by stabilizing brain electrical activity, reducing the frequency and severity of seizures and helping in the management and control of epilepsy. For example, in February 2024, the World Health Organization, a US national agency, reported that globally, around 5 million people are diagnosed with epilepsy each year. High-income countries report an estimated 49 cases per 100,000 people annually, while this rate can rise to 139 cases per 100,000 in low- to middle-income countries. Consequently, the surge in individuals diagnosed with epilepsy is stimulating the growth of the epilepsy drug market._x000D_

_x000D_

#How Is the Epilepsy Drugs Market Segmented?#_x000D_

The epilepsy drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures_x000D_

2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics_x000D_

3) By Route Of Administration: Oral, Intravenous, Intra-Muscular_x000D_

4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Focal Seizures: Simple Focal Seizures, Complex Focal Seizures _x000D_

2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal), Absence Seizures (Petit Mal), Myoclonic Seizures, Tonic Seizures, Atonic Seizures _x000D_

3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES), Functional Seizures_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15564&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Epilepsy Drugs Market Growth?#_x000D_

North America was the largest region in the epilepsy drugs market in 2024. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Epilepsy Drugs Industry?#_x000D_

Key industry players in the epilepsy drug market are concentrating their efforts on creating groundbreaking treatments that not only increase seizure management, but also enrich the lives of patients. These groundbreaking therapies may encompass new drug compositions, superior neurostimulation methodologies, precision medicine strategies that are bespoke to each patient, gene-related treatments, and the advent of technologies such as closed-loop systems designed for seizure detection and response. For instance, in January 2024, Akumentis Healthcare, a pharmaceutical firm from India, unveiled Clasepi, a prescribing CBD drug that has been specifically developed to manage seizures tied to Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and up. It is sanctioned by the Drug Controller General of India (DCGI) and has proven its effectiveness in decreasing seizures, especially in scenarios where traditional anti-seizure medications have failed._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report_x000D_

_x000D_

#How Is the Epilepsy Drugs Market Defined and What Are Its Core Parameters?#_x000D_

Epilepsy drugs, also known as antiepileptic drugs (AEDs) or antiseizure medications, are medications used to manage and control seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent seizures, which can vary widely in type, severity, and frequency. Epilepsy drugs work by stabilizing electrical activity in the brain, reducing the likelihood of seizures occurring._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15564_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theEpilepsy Drugs Market?

The increase in people being diagnosed with epilepsy is anticipated to boost the expansion of the epilepsy drug market. Known as a neurological disorder, epilepsy is characterized by recurring seizures, with varying levels of severity and disruption to daily routines. The elderly and survivors of traumatic brain injuries (TBIs), stroke, brain tumors, and other neurological conditions have a greater likelihood of developing epilepsy. Epilepsy medication works by stabilizing the brain’s electrical activity, lowering the probability and harshness of seizures, hence, helping with epilepsy management and control. For example, the world health organization reported in February 2024 that approximately 5 million people globally are diagnosed with epilepsy each year. High-income countries report an estimated 49 cases annually per 100,000 people, while this rate dramatically increases to 139 cases per 100,000 in low and middle-income countries. Hence, the growing number of people diagnosed with epilepsy is contributing to the upswing of the epilepsy drug market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp

#What Growth Opportunities Will Drive the Epilepsy Drugs Market’s CAGR Through 2034?

The market for epilepsy medications has seen substantial growth in recent years, expanding from a value of $10.34 billion in 2024 to a projected $11.17 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this expansion during the historic period include the advancement of antiepileptic drug development, enhancements in diagnostic tools, a deepened comprehension of epilepsy’s neurological underpinnings, a rise in the demand for epilepsy treatment, and the approval of novel drugs by regulatory bodies.

The market size of epilepsy medications is predicted to witness robust expansion in the upcoming years, reaching $15.11 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 7.9%. The market growth during the prediction span can be credited to the broader adoption of personalized medicine, innovative methods of drug delivery, the advent of digital health technologies, augmented research and development investments, and the incorporation of AI and ML. The forecast period is likely to see major trends such as the inclination towards combination therapies, the rise in telemedicine, emphasis on treating drug-resistant epilepsy, application of genetic testing, and the use of wearable technology devices.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15564

Which Cutting-Edge Market Trends Are Expected to Drive theEpilepsy Drugs Market’s Growth?

In the epilepsy drug market, major corporations are pushing for the creation of novel treatments that not only enhance seizure control but also boost the quality of life of patients. The innovations in epilepsy treatment methods could comprise new drug formulations, cutting-edge neurostimulation techniques, precision medicine options customized for each patient, gene therapies, and emerging technologies like closed-loop systems for detecting and addressing seizures. To illustrate, Akumentis Healthcare, a pharmaceutical firm based in India, introduced Clasepi in January 2024. Clasepi is a cannabidiol (CBD) prescription medicine designed specifically to address seizures in patients aged one year and older, who suffer from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC). It has obtained approval from the Drug Controller General of India (DCGI) and has shown to effectively reduce seizures, especially in instances where traditional anti-seizure medications have failed.

What Are the Leading Market Players Impacting theEpilepsy Drugs Market’s Growth Trend?

Major companies operating in the epilepsy drugs market are Pfizer Inc., SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc., Bausch Health Companies Inc., UCB S.A, Sun Pharmaceutical Industries Ltd., Eisai Co Ltd., Sumitomo Pharma Co Ltd., Jazz Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd., Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc., Upsher-Smith, Zogenix, Neurelis Inc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

How Are the Key Segments of the Epilepsy Drugs Market Driving Opportunities and Innovations?

The epilepsy drugs market covered in this report is segmented –

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures

2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics

3) By Route Of Administration: Oral, Intravenous, Intra-Muscular

4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies

Subsegments:

1) By Focal Seizures: Simple Focal Seizures, Complex Focal Seizures

2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal), Absence Seizures (Petit Mal), Myoclonic Seizures, Tonic Seizures, Atonic Seizures

3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES), Functional Seizures

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15564&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theEpilepsy Drugs Market?# Market Expansion?

North America was the largest region in the epilepsy drugs market in 2023. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Epilepsy Drugs Market 2025, By The Business Research Company:

Intravascular Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intravascular-catheters-global-market-report

Transcatheter Valve Repair System Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/transcatheter-valve-repair-system-global-market-report

Peripheral IV Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peripheral-iv-catheters-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Epilepsy Drugs Market During the Forecast Period, and Why?

In recent times, the market size for epilepsy drugs has witnessed a robust expansion. It is projected to increase from $10.34 billion in 2024 to $11.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.1%. Several factors can be credited for this growth observed in the historic period. Such factors include the evolution of antiepileptic drugs, progression in diagnostic methodologies, enhanced comprehension of the neurological underpinnings of epilepsy, a rising demand for epilepsy therapies, and approval of new medications by regulatory authorities.

The market size for epilepsy drugs is predicted to experience substantial growth in the coming years, estimating a rise to $15.11 billion by 2029 with a compound annual growth rate (CAGR) of 7.9%. This expected growth during the forecast period is due to factors such as the expansion of personalized medicine, the use of innovative drug delivery techniques, the advent of digital health solutions, increased funding for research and development, and the inclusion of AI and ML. Notable trends expected during the forecast period involve a move toward composite therapies, the emergence of telemedicine, a focus on drug-resistant epilepsy, integrating genetic testing, and the use of wearable devices.

How Are the key drivers Contributing to the Expansion of the Epilepsy Drugs Market?

An increase in the population suffering from epilepsy is anticipated to fuel the expansion of the epilepsy drug market in the future. Epilepsy, characterized by repetitive seizures varying in gravity and everyday life impact, is a neurological disorder. It’s more common among the elderly and those who have survived traumatic brain injuries (TBIs), strokes, brain tumours, and other neurological conditions are at an elevated risk of contracting epilepsy. Epilepsy medications work by maintaining a steady electrical activity in the brain, thereby diminishing the probability and severity of seizures, providing management and control over epilepsy. For example, the World Health Organization, a US-based national agency, stated in February 2024 that globally, about 5 million people are diagnosed with epilepsy each year, with high-income countries documenting about 49 cases per 100,000 individuals annually. In contrast, in low- and middle-income countries, this number can skyrocket to 139 cases per 100,000. Thus, the increasing number of individuals inflicted with epilepsy is accelerating the growth of the epilepsy drug market.

Request Your Free Epilepsy Drugs Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp

Which Companies Are Poised to Shape the Future of the Epilepsy Drugs Market?

Major companies operating in the epilepsy drugs market are:

• JPMorgan Chase & Co._x000D_

• HSBC Holdings plc_x000D_

• Morgan Stanley_x000D_

• BNP Paribas Asset Management S.A._x000D_

• The Goldman Sachs Group Inc._x000D_

What Are the Latest Innovations and Trends Influencing the Epilepsy Drugs Market?

Key players in the epilepsy drug market are stepping up their game by creating revolutionary treatments aimed at better managing seizures and boosting the well-being of patients. This innovation in epilepsy remedies can mean the creation of distinct drug combinations, the exploration of avant-garde neurostimulation techniques, the crafting of precision medicine that’s unique to each patient, the development of gene therapies, and the advent of new-age technologies like automated systems for identifying and treating seizures. Taking this into account, Akumentis Healthcare, a pharmaceutical business based in India, set new standards by introducing Clasepi in January 2024. This drug, containing prescription cannabidiol (CBD), is specifically engineered to handle seizures paired with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients who are at least 1 year old. Endorsed by the Drug Controller General of India (DCGI), Clasepi has shown potential in decreasing seizures, especially when traditional anti-seizure medicines have failed to show results.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Which Industry Segments Are Leading the Development and Expansion of the Epilepsy Drugs Market?

The epilepsy drugs market covered in this report is segmented –

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures

2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics

3) By Route Of Administration: Oral, Intravenous, Intra-Muscular

4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies

Subsegments:

1) By Focal Seizures: Simple Focal Seizures, Complex Focal Seizures

2) By Generalized Seizures: Tonic-Clonic Seizures (Grand Mal), Absence Seizures (Petit Mal), Myoclonic Seizures, Tonic Seizures, Atonic Seizures

3) By Non-Epileptic Seizures: Psychogenic Non-Epileptic Seizures (PNES), Functional Seizures

What Regions Are Contributing Significantly to the Growth of the Epilepsy Drugs Market?

North America was the largest region in the epilepsy drugs market in 2023. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Epilepsy Drugs Market Defined?

Epilepsy drugs, also known as antiepileptic drugs (AEDs) or antiseizure medications, are medications used to manage and control seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent seizures, which can vary widely in type, severity, and frequency. Epilepsy drugs work by stabilizing electrical activity in the brain, reducing the likelihood of seizures occurring.

Browse Through More Similar Reports By The Business Research Company:

Intravascular Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intravascular-catheters-global-market-report

Transcatheter Valve Repair System Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/transcatheter-valve-repair-system-global-market-report

Peripheral IV Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peripheral-iv-catheters-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: